Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Grazia CasavecchiaGiuseppina SpinosaLuisa De GennaroStefano ZicchinoMatteo GravinaMichele MagnesaMatteo Di BiaseNatale Daniele BrunettiPublished in: Acta cardiologica (2021)
In patients with CML treated with TKIs, therapy with ponatinib was associated with a higher risk of CVE than other TKIs. The lowest incidence of CVE was associated with bosutinib and nilotinib.